Innoviva Market Cap 2010-2024 | INVA

Innoviva market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Innoviva market cap as of April 02, 2025 is $1.14B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.136B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $783.103B 63.53
Johnson & Johnson (JNJ) United States $399.649B 16.60
AbbVie (ABBV) United States $370.636B 20.70
Novo Nordisk (NVO) Denmark $311.614B 21.11
Roche Holding AG (RHHBY) Switzerland $262.452B 0.00
Novartis AG (NVS) Switzerland $227.865B 14.27
Merck (MRK) United States $226.737B 11.75
Pfizer (PFE) United States $143.715B 8.15
Sanofi (SNY) $140.749B 13.33
Bayer (BAYRY) Germany $23.657B 4.39